NCT04944082.

Study name	Remdesivir‐ivermectin combination therapy in severe Covid‐19
Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 60 Setting: inpatient Country: Egypt Language: English Number of centres: NR Study purpose (treatment, prevention): treatment Trial registration number: NCT04944082 Date of registration: 29 June 2021
Participants	Inclusion criteria Adult, hospitalized severe COVID‐19 patients Both genders Given informed consent (COVID‐19 infection confirmed by PCR, severe illness is defined as patients with SpO2 ≤ 94% on room air, including patients on supplemental oxygen) Exclusion criteria Patients under 18 years old Pregnant women Advanced renal diseases (cr. clearance < 30 mL/hr) Raised liver enzymes > 3 times normal Arrhythmia
Interventions	Details of intervention Type and dose: ivermectin 6 mg, once daily for 4 days Route of administration: oral Treatment details of control group Standard of care alone Concomitant therapy: standard of care (remdesivir) administered in both study arms
Outcomes	Primary study outcome Improvement in level of oxygenation Need for ventilator support Development of complication by end of 4th day Mortality rate Relevant review outcomes planned Need for ventilator support Mortality rate Development of complication by end of 4th day Additional study outcomes None
Starting date	1 July 2021
Contact information	Maiada K. Hashem Lecturer Assiut University, Department of Chest Diseases Assiut Egypt
Notes	Recruitment status: not yet recruiting Prospective completion date: December 2021 Planned completion date more than 6 months ago: no Date last update posted: 29 June 2021 Sponsor/funding: Assiut University